Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
AssigneeThe Procter & Gamble Company
InventorKevin Gene Peters
Life of this patent
Estimating the term…
Abstract
KDR associated phosphatase (KAPh) is useful as a target to screen for agents useful for the treatment of angiogenesis mediated disorders.
Claims17
An isolated polypeptide of SEQ ID NO 2 or variant thereof.
An isolated nucleotide of SEQ ID NO 1 or variant thereof.
A method of using KAPh, or variant thereof, in the treatment of an angiogenesis mediated disorder in a subject in need thereof.
A method of screening an agent useful for treating an angiogenesis mediated disorder comprising the steps of:
- a. exposing KAPh, or variant thereof, to the agent;
- and
- b. measuring activity of KAPh;
- wherein a modulation in KAPh activity indicates the agent is useful for treating the angiogenesis mediated disorder.
A method of screening an agent useful for modulating angiogenesis comprising the steps of:
- a. exposing KAPh, or variant thereof, to the agent;
- b. exposing KAPh to VEGFR2;
- and
- c. measuring association of KAPh and VEGFR2;
- wherein a modulation is the association of KAPh and VEGFR2 indicates the agent is useful for treating the angiogenesis mediated disorder.
A method of screening an agent useful for treating an angiogenesis mediated disorder comprising the steps of:
- a. exposing a cell to the agent;
- and
- b. measuring activity of KAPh in the cell;
- wherein a modulation in the expression or the activity of KAPh indicates the agent is useful for treating the angiogenesis mediated disorder.
A method of screening an agent useful for treating an angiogenesis mediated disorder comprising the steps of:
- a. exposing a cell to the agent;
- and
- d. measuring association of KAPh and VEGFR2;
- wherein a modulation is the association of KAPh and VEGFR2 indicates the agent is useful for treating the angiogenesis mediated disorder.
A method of screening an agent useful for treating an angiogenesis mediated disorder comprising the steps of:
- c. exposing a cell to the agent;
- and
- d. measuring expression of KAPh in the cell;
- wherein a modulation in the expression or the activity of KAPh indicates the agent is useful for treating the angiogenesis mediated disorder.
An antibody binding KAPh or variant thereof.
Dependencies are inferred from the claim text.